Page results
-
All GPs are now welcome to use our national Infectious & Tropical Disease Advice and Guidance function on the e-referral system (NHS e-RS)
-
Our outpatient clinics will remain predominantly virtual throughout the COVID-19 pandemic. Please continue to refer via the NHS e-referral service.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
Dr Manjit Matharu's major research interests include migraine, trigeminal autonomic cephalalgias, facial pain, neurostimulation for intractable headaches, spontaneous intracranial hypotension and other headache disorders in hypermobility syndromes.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.
-
John McGrath is a newly appointed governor as a stakeholder member from North Central London Clinical Commissioning Group (CCG). He is a local GP and has lived and worked in Islington for the last decade in a number of different settings, including multiple GP surgeries as a salaried doctor, local A&E departments and urgent care.
-
London’s Business Design Centre opens its doors this week as a large- scale COVID-19 vaccination facility.
File results
-
FOI/2023/0281 - Bariatric equipment
-
FOI/2023/0282 - British Medical Association (BMA) strikes - cancelled, delayed or missed appointments
-
FOI/2023/0284 - IT services management platform/ user licences
-
FOI/2023/0286 - Maternity services budget for 2018/19-2022/23
-
FOI/2023/0288 - Cancer treatment capacity
-
FOI/2023/0290 - Specialist palliative care units within the Trust
-
FOI/2023/0294 - Patient entertainment
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine